proco
Ingredients · Sleep

Magnesium Glycinate: Clinical Dose Ranges and What the Research Describes

Proco Editorial · 2026-06-04 · 7 min read

This page is educational. It describes what published research has measured about magnesium glycinate. It is not medical advice and does not replace consultation with a qualified healthcare professional.

Dose thresholds shown here reflect ranges used in published clinical trials, not dosing recommendations. Whether any dose is appropriate for an individual depends on factors this page cannot assess.


What magnesium glycinate is

Magnesium glycinate is a chelated form of magnesium in which magnesium is bound to glycine, a non-essential amino acid. It is one of several supplemental magnesium forms — others include oxide, citrate, malate, and threonate — and is broadly regarded as among the better-absorbed oral forms, with lower rates of gastrointestinal side effects than oxide.

Magnesium is an essential mineral involved in over 300 enzymatic processes, including energy production, protein synthesis, and nerve transmission. UK dietary surveys consistently find a significant proportion of adults with intakes below recommended levels, making supplementation in those with genuine dietary insufficiency plausible.

For a detailed look at what the research says specifically about magnesium glycinate and sleep, see: What the research says about magnesium glycinate and sleep.


The clinical dose range

Scanner database range: 300–400 mg/day elemental magnesium. This reflects the range used in trials measuring sleep and anxiety outcomes. The critical figure is the elemental magnesium content — not the total weight of the magnesium glycinate compound. Magnesium glycinate typically contains approximately 14% elemental magnesium by weight, so a product listing 2,000 mg magnesium glycinate delivers approximately 280 mg elemental magnesium.

Many product labels list the weight of the compound rather than elemental magnesium content. Comparing products without checking the elemental figure makes dose assessment unreliable.


What trials have measured

The trial evidence for magnesium supplementation specifically and sleep is limited in volume and methodological quality. Most trials in this area have studied older adults with probable deficiency, not healthy younger adults. A 2012 randomised controlled trial of 46 older adults with insomnia found improvements in sleep quality scores, sleep onset latency, and serum melatonin concentration after 8 weeks of 500 mg/day elemental magnesium. A subsequent meta-analysis of randomised trials found small improvements in sleep efficiency and sleep time, but cautioned that most included studies had high risk of bias.

For anxiety and subjective stress, the trial base is similarly modest. A 2017 systematic review found some evidence of benefit in mildly anxious populations, but could not exclude placebo response given the largely subjective outcome measures.

Muscle cramp and exercise recovery outcomes have been studied in athletes and older adults, with more mixed results. The strongest evidence for magnesium's health role relates to cardiovascular function, bone mineral density, and glucose metabolism — areas studied in epidemiological research linking dietary magnesium intake to health outcomes, which is a different evidence type from supplementation trials.

Evidence quality note: Most supplementation trials are short, small, and conducted in populations with likely deficiency. Results may not generalise to individuals with adequate dietary magnesium intake.

Underdosing in commercial products

The most common underdosing pattern with magnesium glycinate is label ambiguity rather than an outright low dose. Products list the compound weight (e.g. 1,000 mg magnesium glycinate) without displaying elemental magnesium content on the front of the label, making it easy for buyers to assume they are receiving 1,000 mg of elemental magnesium when the actual figure is approximately 140 mg.


Documented safety considerations

Magnesium glycinate is generally well tolerated at the studied doses. Excessive magnesium supplementation can cause gastrointestinal effects including loose stools, though glycinate causes less laxative effect than oxide or citrate forms. At very high supplemental doses, hypermagnesaemia is a theoretical risk, particularly in individuals with impaired kidney function — the kidneys are the primary route of magnesium excretion. People with kidney disease should not supplement without medical supervision.

The EU tolerable upper intake level for supplemental magnesium is 250 mg/day. Some trial protocols exceed this level. The UK NHS advises not to take more than 400 mg/day from supplements.


How Proco Scanner evaluates it

When the Scanner reads a magnesium glycinate ingredient, it checks the declared elemental magnesium content — not the compound weight — against the 300–400 mg/day range used in sleep and anxiety trials. Products that list compound weight only, without elemental content, are flagged as insufficient for dose verification.

Proco Scanner reads any supplement label and surfaces what the published research describes for each ingredient — dose, evidence quality, and known considerations. Coming to iOS. Join the waitlist for early access.

Proco provides educational, research-based information. It does not diagnose, treat, cure, or prevent any condition. Individual responses to supplementation vary based on training status, diet, health status, and other factors. If you are pregnant, breastfeeding, take prescription medication, manage a chronic condition, or are considering supplementation for a child, talk to a qualified healthcare professional before relying on any information from Proco.

If you are experiencing a medical emergency, contact your local emergency services.

Proco Scanner

Check your magnesium dose. Instantly.

Proco Scanner reads any supplement label and checks the elemental magnesium content — not just the compound weight — against clinical trial doses. Coming to iOS.

Request early access No spam. We email when access opens.